TAONas-LUAD

Today we launch a series on aberrant splicing and its role in genetic diseases. This first piece lays the foundation, starting with what alternative splicing is and how it works at the molecular level. 🔬 Stay tuned for more on the science behind our research.

7 April 2026 | #WorldHealthDay 🌍 At TAONas-LUAD, we #StandWithScience and support WHO’s mission for a healthier world. Advancing ASOs for RNA diseases, we aim to deliver personalised treatments globally with #AlternaTherapeutics.

New update on the @TaonasL website! Our latest blog revisits key concepts behind our research, from molecular biology basics to the role of alternative splicing in gene regulation and RNA-related diseases. Read more: taonas.eu/aberrant-splic…

TAONas-Talks | Episode 4 🎙️ We’re back with our researchers! Meet Jérémie Parot, Senior Research Scientist at @SINTEF, as he dives into LNP design for safe & efficient ASO delivery. From preclinical results to the future of drug delivery—don’t miss it!

Hard work pays off! 🚀 Proud to see Alterna Therapeutics (EIC Transition @TaonasL spin-off) named a Top 10 Company to Watch by @LSciNation. Big thanks to Maria Buxadé Fortuny for driving our RNA therapies forward. 2026 looks bright! ✨ 👉 blog.lifesciencenation.com/2025/12/16/com…

TAONas-Talks | Ep. 3 🎙️ Meet Maria Buxade, CEO of Alterna Therapeutics, TAONas-LUAD’s future spin-off. With 25+ years in immunology & biotech leadership, Maria shares what led her to take the CEO role, investor feedback, project progress, and what’s next for Alterna Tx.

A special milestone for TAONas-LUAD 🚀 As the final year of our EIC Transition project ends, we reflect on 3.5+ years advancing antisense therapies for lung cancer. The journey continues beyond EIC funding—toward more tangible outcomes in 2026. Stay tuned & happy new year!

Happy holidays from the @TaonasL team! 🎄 Thank you for supporting our work on lung cancer. We’re taking a short break to recharge and will be back soon with renewed energy—continuing the fight against cancer with the power of science.

TAONas-LUAD ends soon after 3 years of EIC-backed work. Which has it been its main focus, continued by CRG spin-off “Alterna Therapeutics”?

Maria Buxadé Fortuny, CEO of Alterna Therapeutics (soon-to-be @CRGenomica spin-off), will be at RESI London next week. A great chance to showcase our RNA-targeted therapeutic tech and connect with investors and partners. Attending RESI? Let’s meet!

Hear his insights on: ✅Advances in lung adenocarcinoma research ✅CRG’s role in collaboration & innovation ✅The future of TAONas & spin-off Alterna Therapeutics

🚀 TAONas-Talks Ep. 2 is out! Featuring Juan Valcárcel (@CRGenomica), a leading voice in #MolecularBiology and coordinator of @TaonasL. Don’t miss this conversation with interviewer Marc Dominguez! #TAONasTalks #CRG #LungCancerResearch

🔬 @SINTEF, one of Europe’s largest research institutes, has designed and optimized LNPs for targeted ASO delivery to lung tissue in @TaonasL 60× higher efficacy than naked ASOs in lung cancer models.

We’re heading to #BIOEurope2025 in Vienna. Maria Buxadé, CEO of our @TaonasL spin-off, will: • Build alliances with biotech and pharma leaders • Engage investors for our AI-powered RNA platform • Showcase our therapeutic vision for cancer and RNA diseases

🚀 Exciting news from Alterna Therapeutics! Our CEO Maria will attend the 21st Annual @OTSociety Meeting in Budapest (Oct 19–22) — the premier global event for RNA & antisense experts. Stay tuned for updates from #OTS2025!

🌍 @BIOSPAIN_AseBio 2025 (Oct 7–9, Barcelona) will gather 2,500+ biotech leaders & 1,000+ orgs worldwide. For Alterna Therapeutics, it’s a chance to spotlight our ASO therapies, engage KOLs & forge partnerships in the fast-growing RNA space. See you in Barcelona! #BIOSPAIN2025

🔬 Meet our coordinator: @CRGenomica in Barcelona! CRG, led by Dr. Juan Valcárcel’s lab, pioneers research on alternative splicing to drive new RNA-based therapies. Their expertise bridges discovery & application, from cancer biology to spin-off creation. #RNAtherapeutics

Maria Buxadé Fortuny, CEO of AlteRNA Therapeutics (spin-off from EU Project @TaonasL ), joins #RESIBoston 2025 virtually to showcase our antisense RNA platform, meet oncology investors, and explore Dx & VC opportunities. #TAONAS #AlteRNA #RNAASOs #BiotechFunding

Meet IRCM-INSERM: experts in preclinical validation and translational cancer research. Their advanced lung cancer models are key to bringing our @TaonasL RNA therapy from discovery to the clinic. #CancerResearch #LungCancer

Maria Buxadé, CEO of the future @TaonasL spin-off Alterna Therapeutics, is at #AdvancedTherapiesEurope. The event supports our goals: – Stay current on RNA ASOs and gene therapy – Meet biotech leaders, investors, regulators – Build visibility for Alterna in EU drug development